Shop Research Compounds
Home / Shop / melanotan-ii
melanotan-ii research product by Crystal Peptides
Skin & Anti-Aging

melanotan-ii

10mg/vial

Synthetic alpha-MSH analog studied around pigmentation and melanocortin receptor signaling in skin-biology research models.

€60,00
Third-party testedCOA availableEU shippingResearch only
For in-vitro laboratory research only. Not for human or veterinary use.This information is provided for scientific and educational product context only. It does not describe or recommend human use, veterinary use, diagnosis, treatment, prevention, dosage, administration, or clinical application.
Research intelligence

Research context for Melanotan II

This information is provided for scientific and educational product context only. It does not describe or recommend human use, veterinary use, diagnosis, treatment, prevention, dosage, administration, or clinical application.

Product research overview

Melanotan II is a synthetic cyclic heptapeptide analog of alpha-MSH and a melanocortin-receptor agonist used in receptor, pigmentation, energy-balance, and behavioral/endocrine research. It is not presented as an approved tanning or therapeutic product.

MaterialCyclic alpha-MSH analog
Primary areaMelanocortin receptor signaling
EvidencePreclinical and early human investigation
CatalogSkin & Anti-Aging

Mechanism & pathway context

  • Melanocortin receptors are G-protein-coupled receptors whose signaling commonly involves cyclic AMP, with subtype-specific tissue distribution.
  • MT-II is a nonselective melanocortin agonist; experimental findings can involve both canonical receptor pathways and off-target/model-specific effects.

Melanocortin receptors

Receptor subtype pharmacology and cAMP signaling.

Pigmentation models

Melanocyte and melanogenic pathway endpoints.

Energy balance

Central melanocortin signaling in animal models.

Behavioral/endocrine

Model-based central and peripheral responses.

What researchers study

  • MC1R-MC5R activation profiles
  • cAMP and downstream pigmentation markers
  • Animal metabolic and thermoregulatory endpoints
  • Adverse-response and off-target signals

Current evidence snapshot

Evidence areaResearch contextStrengthNotes
Receptor pharmacologyCell and animal studiesPreclinicalNonselective melanocortin agonism is well described.
Early human researchSmall phase 1-era studiesEarly / investigationalSmall studies do not establish approved use.
Safety and approvalStorefront productLimitedNo approved tanning or clinical claim is made.

Limitations & safety boundaries

  • This storefront supplies research reference material only; research findings do not establish consumer outcomes.
  • Evidence may be limited to cell, tissue, or animal models and may not translate to humans.
  • No dosing, administration, preparation, or clinical guidance is provided.
  • Researchers and buyers are responsible for institutional requirements and applicable local laws.

For in-vitro laboratory research only. Not for human or veterinary use.